Interpace Biosciences IDXG Insider Ownership

Updated Oct 5, 2026

Across the past 12 months, Interpace Biosciences insiders reported no open-market purchases or sales.

• Away from the open market, IDXG insiders acquired 23.54Mn shares through option exercises and conversions over the last 12 months.
• Per Business Quant, IDXG insiders together hold 23.59Mn shares based on their latest Form 4 filings, or 85.16% of the 27.7Mn shares outstanding; that total is up 1.19% from 23.31Mn shares at the end of Q2 2026.
• All of the 23.59Mn shares held by Interpace Biosciences insiders are held directly, none through trusts, partnerships or other entities.
• Per Business Quant, 3 insiders of IDXG hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Interpace Biosciences' three biggest insider holders are Ampersand 2018 Limited Partnership (10% owner, 13.86Mn shares), 1315 Capital II, L.P. (10% owner, 9.41Mn shares) and Christopher McCarthy (CFO & COO, 323.8K shares), based on their latest Form 4 filings.
• The holding of Ampersand 2018 Limited Partnership makes up 58.76% of all shares held by Interpace Biosciences insiders.
• In the last 12 months, 5 Form 4 filings with transactions in IDXG stock came from 5 insiders.
• This summary of Interpace Biosciences insider activity covers Form 4 filings through August 20, 2026.